Advertisement

Journal of Radioanalytical Chemistry

, Volume 79, Issue 2, pp 355–361 | Cite as

Kinetics of 17-(123I) iodoheptadecanoic acid in myocardium of rats

  • S. N. Reske
  • G. Auner
  • C. Winkler
Medical Radionuclides and the Quality of Radiopharmaceuticals

Abstract

Myocardial uptake and turnover of 17-(123I)-iodoheptadecanoic acid, injected i.v., was studied in rats. Kinetics of radioactivity incorporated into myocardial tissue and heart lipids as well as myocardial radioactivity recovered as123I iodide were determined. Maximal heart uptake of IHA (7.9% dose/g heart) was observed as early as 30 sec., p.i., followed by mono-component elimination period. Already 10 to 30 sec p.i. 70 to 80% of total myocardial radioactivity was recovered as123I iodide. IHA was incorporated only in modest amounts into myocardial phospholipids and triglycerides. Time course of total myocardial radioactivity grossly paralleled that recovered as123I iodide. These findings indicate stringent limitations in utility of IHA as a tracer for assessment of β-oxidation.

Keywords

Myocardial Uptake Anion Exchange Column Thin Layer Chroma Free Fatty Acid Fraction Radioactivity Uptake 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. R. SCHELBERT, E. HENZE, M. E. PHELPS, Sem. Nucl. Med., X (1980) 355.Google Scholar
  2. 2.
    M. M. TER-POGOSSIAN, M. S. KLEIN, J. MARKHAM, R. ROBERTS, B. E. SOBEL, Circulation, 61 (1980) 242.Google Scholar
  3. 3.
    I. R. EVANS, R. W. GUNTRON, R. G. BAKER, D. S. BEANLANDS, B. C. SPEARS, Circ. Res., 16 (1965) 1.Google Scholar
  4. 4.
    N. D. POE, C. P. ROBINSON, F. W. ZIELINSKI, W. R. CABEEN, J. W. SMITH, A. S. GOMES, Radiology, (1977) 419.Google Scholar
  5. 5.
    H. J. MACHULLA, G. STOECKLIN, C. KUPFERNAGEL, C. FREUNDLIEB, A. HOECK, K. VYSKA, L. E. FEINENDEGEN, J. Nucl. Med., 19 (1978) 298.Google Scholar
  6. 6.
    C. FREUNDLIEB, A. HOECK, K. VYSKA, L. E. FEINENDEGEN, H. J. MACHULLA, G. STOECKLIN, J. Nucl. Med., 21 (1980) 1043.Google Scholar
  7. 7.
    R. KLINE, H. RIZZI, T. MANGNER, M. BESOZZI, J. THRALL, D. SANSON, J. COPP, C. BROWN, J. Nucl. Med., 22 (1981) 29 (abst).Google Scholar
  8. 8.
    H. EGGE, U. MURAWSKI, J. MUELLER, F. ZILLIKEN, Z. Chem. Klin. Biochem., 5 (1970) 499.Google Scholar
  9. 9.
    H. J. DAUS, S. N. RESKE, K. VYSKA, L. E. FEINENDEGEN, in: Nuklearmedizin, H. A. E. SCHMIDT, F. WOLF, (Eds), F. K. Schattauer, Stuttgart, 1981, p. 108.Google Scholar
  10. 10.
    C. A. OTTO, L. E. BROWN, D. M. WIELAND, W. H. BEIERWALTES, J. Nucl. Med., 22, (1981) 613.Google Scholar
  11. 11.
    O. STEIN, Y. STEIN, J. Cell Biol., 36 (1968) 63.CrossRefGoogle Scholar
  12. 12.
    G. A. THOMPSON, in: Comprehensive Biochemistry, M. FLORKIN, E. H. STOTZ, (Eds) Elsevier Publ. Comp., Amsterdam, 1970, p. 157.Google Scholar
  13. 13.
    J. GLOSTER, M. ACHILLEA, P. HARRIS, J. Mol. Cell. Cardiol., (1978) 439.Google Scholar
  14. 14.
    R. E. OLSON, R. J. HOESCHEN, Biochem. J. 103, (1967) 796.Google Scholar

Copyright information

© Akadémiai Kiadó 1985

Authors and Affiliations

  • S. N. Reske
    • 1
  • G. Auner
    • 1
  • C. Winkler
    • 1
  1. 1.Institute of Clinical and Experimental NuclearMedicine University of BonnFRG

Personalised recommendations